I-Mab to Present at the BTIG Virtual Biotechnology Conference
Rhea-AI Summary
I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company specializing in precision immuno-oncology agents for cancer treatment, has announced its participation in the upcoming BTIG Virtual Biotechnology Conference. The company's management will engage in a fireside chat and one-on-one meetings on Tuesday, July 29, 2025, at 10:00 AM ET.
The presentation will be available via webcast on I-Mab's website under the News & Events section, remaining accessible for 90 days following the event.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – IMAB
On the day this news was published, IMAB gained 0.47%, reflecting a mild positive market reaction. This price movement added approximately $802K to the company's valuation, bringing the market cap to $171.49M at that time.
Data tracked by StockTitan Argus on the day of publication.
ROCKVILLE, Md., July 14, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in the BTIG Virtual Biotechnology Conference, being held on July 29-30, 2025.
Conference details are as follows:
BTIG Virtual Biotechnology Conference
Format: Fireside Chat and one-on-one meetings
Date: Tuesday, July 29, 2025
Time: 10:00 AM ET
Webcast Link: Available on the News & Events page of the I-Mab website
The webcast of the event will be accessible from News & Events page of the I-Mab website for 90 days.
About I-Mab
I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. The Company’s differentiated pipeline is led by givastomig, a potential best-in-class, bispecific antibody (Claudin 18.2 x 4-1BB) designed to treat Claudin 18.2-positive gastric cancers. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed for first-line metastatic gastric cancers, with additional potential in other solid tumors. In Phase 1 trials, givastomig was observed to maintain strong tumor-binding and anti-tumor activity, attributable to a potential synergistic effect of proximal interaction with Claudin 18.2 and 4-1BB, while minimizing toxicities commonly seen with other 4-1BB agents.
For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.
I-Mab Investor & Media Contacts
| PJ Kelleher | |
| LifeSci Advisors | |
| +1-617-430-7579 | |
| pkelleher@lifesciadvisors.com | |
| IR@imabbio.com |
